尼莫地平能透过血脑屏障,扩张颅内血管,能改善梗阻部位周围的血管内血流量,副作用少而轻微,为降低急性缺血性率中提供了希望。曾报告用药后致残率和死亡率均有所下降。本文采随机、双盲、多中心、安慰剂对照试验,评价尼莫地平降低急性缺血性率中(AIS)致残率和死亡率的有效性与安全性。方法:患者CT证实过去无梗塞或出血、有明确的发病时间、均是在发病后48小时内CT检查确诊。凡昏迷、脑出血、出血性梗塞、脑肿瘤、颅内出血、感染、脑水肿及其它原发性脑疾病和心肺肝肾的严重疾患、妊娠、低电压、心动过缓等,均不列入观察对象。患者未使用过钙拮抗剂。研究对象年龄21～89岁(平均66岁)共1064例,58%男性。其中65%白人,25%黑人。随机分为四组、一组安慰剂组,另三组 Nimodipine can penetrate the blood-brain barrier, dilate the intracranial blood vessels, can improve the blood flow around the obstruction site with little and minor side effects, which provide hope for reducing acute ischemic rate. Once reported, the morbidity and mortality rates dropped after treatment. This randomized, double-blind, multicenter, placebo-controlled trial evaluated the efficacy and safety of nimodipine in reducing the morbidity and mortality of acute ischemic attacks (AIS). Methods: CT confirmed in the past without infarction or bleeding, a clear time of onset, are diagnosed within 48 hours after onset of CT examination. All coma, cerebral hemorrhage, hemorrhagic infarction, brain tumor, intracranial hemorrhage, infection, cerebral edema and other primary brain diseases and severe diseases of heart, liver and kidney, pregnancy, low voltage and bradycardia are not included in the observation Object Patients did not use calcium antagonists. The subjects were 1064 and 58% males, aged 21 to 89 years (mean, 66 years). 65% of whites and 25% of blacks. Randomly divided into four groups, one placebo group and the other three groups